Aub Sante
- Address
- lock Available on a paid plan
Nephrology and Cardiovascular Diseases
At Aub Sante in Saint-Gregoire, clinical research in Nephrology is closely linked with Cardiovascular Diseases, focusing on people with moderate to severe chronic kidney disease and uncontrolled hypertension. These studies are designed to evaluate better ways to control blood pressure and reduce the risk of kidney decline and related heart complications.
- Uncontrolled hypertension in chronic kidney disease
- End-stage renal disease prevention
- Cardiovascular risk reduction in kidney disease
The research aims to test improved treatment strategies, including approaches that may help slow disease progression and lower the chances of major cardiovascular events.
Therapeutics in Kidney Disease Care
This site is also studying Analytical, Diagnostic and Therapeutic Techniques and Equipment with a strong therapeutic focus on patients affected by end-stage renal disease. The work explores whether new treatment approaches can improve outcomes for people living with advanced kidney failure and related complications.
- End-stage renal disease
- Chronic kidney disease progression
- Treatment effectiveness in advanced renal disease
One area of interest is assessing whether targeted management strategies can better protect kidney function and support longer-term health.
Male Urogenital Diseases and ANCA Vasculitis
Clinical trials at Aub Sante also address Male Urogenital Diseases through research in ANCA vasculitis and end-stage renal disease. These studies are examining how to optimize care for patients whose kidney disease is linked to autoimmune inflammation and who may need decisions about continuing or stopping immunosuppressive treatment.
- ANCA vasculitis
- End-stage renal disease
- Immunosuppression management
The purpose is to compare treatment approaches and determine whether changing long-term therapy can improve safety and overall patient outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Aub Sante
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparative Safety and Efficacy of Apixaban Versus Warfarin in Patients with End-Stage Renal Disease on Peritoneal Dialysis and Non-Valvular Atrial Fibrillation | Centre Hospitalier Universitaire De Caen Normandie | Phase III | Recruiting | Jan 2025 | — |
IMP list
lock Showing 1 of 12 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Amiloride Hydrochloride | 1 | Unknown | 2023-03-28 | 2023-03-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.